Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma

Journal of Clinical Oncology

Volumn 35, Issue 14, 2017, Pages 1598-1605

  Gibson, Christopher J ^a   Lindsley, R Coleman ^a   Tchekmedyian, Vatche ^e   Mar, Brenton G ^a   Shi, Jiantao ^a,b   Jaiswal, Siddhartha ^c   Bosworth, Alysia ^f   Francisco, Liton ^g   He, Jianbo ^g   Bansal, Anita ^f   Morgan, Elizabeth A ^c   Lacasce, Ann S ^a   Freedman, Arnold S ^a   Fisher, David C ^a   Jacobsen, Eric ^a   Armand, Philippe ^a   Alyea, Edwin P ^a   Koreth, John ^a   Ho, Vincent ^a   Soiffer, Robert J ^a   Antin, Joseph H ^a   Ritz, Jerome ^a   Nikiforow, Sarah ^a   Forman, Stephen J ^f   Michor, Franziska ^a,b   Neuberg, Donna ^a   Bhatia, Ravi ^g   Bhatia, Smita ^g   Ebert, Benjamin L ^c,d   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASXL1 PROTEIN, HUMAN; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE 3A; ONCOPROTEIN; PPM1D PROTEIN, HUMAN; PROTEIN P53; PROTEIN PHOSPHATASE 2C; REPRESSOR PROTEIN; TET2 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ADVERSE EFFECTS; AGED; AUTOTRANSPLANTATION; CELL CLONE; DNA MUTATIONAL ANALYSIS; EXOME; FEMALE; GENETICS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; CLONE CELLS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; EXOME; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; PROTEIN PHOSPHATASE 2C; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85019060879     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.71.6712     Document Type: Article

References (24)

1. Jaiswal S, Fontanillas P, Flannick J, et al: Agerelated clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371:2488-2498, 2014
2. Genovese G, Kähler AK, Handsaker RE, et al: Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371:2477-2487, 2014
3. XieM, Lu C, Wang J, et al: Age-relatedmutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20:1472-1478, 2014
4. McKerrell T, Park N, Moreno T, et al: Leukemiaassociated somaticmutations drive distinct patterns of agerelated clonal hemopoiesis. Cell Rep 10:1239-1245, 2015
5. Young AL, Challen GA, Birmann BM, et al: Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun 7:12484, 2016
6. Steensma DP, Bejar R, Jaiswal S, et al: Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126:9-16, 2015
7. Larson RA, Wernli M, Le Beau MM, et al: Short remission durations in therapy-related leukemia despite cytogenetic complete responses to highdose cytarabine. Blood 72:1333-1339, 1988
8. Swerdlow S, Campo E, Harris N, et al: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (ed 4). Geneva, Switzerland, WHO, 2008
9. Smith SM, Le Beau MM, Huo D, et al: Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood 102:43-52, 2003
10. Kayser S, Dö hner K, Krauter J, et al: The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117:2137-2145, 2011
11. Lindsley RC, Mar. BG, Mazzola E, et al: Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125:1367-1376, 2015
12. Wong TN, Ramsingh G, Young AL, et al: Role of TP53 mutations in the origin and evolution of therapyrelated acute myeloid leukaemia. Nature 518:552-555, 2015
13. Friedberg JW, Neuberg D, Stone RM, et al: Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 17:3128-3135, 1999
14. Sevilla J, Rodríguez A, Hernández-Maraver D, et al: Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation. Ann Hematol 81:11-15, 2002
15. Ladetto M, Vallet S, Benedetti F, et al: Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: Updated results of the multicenter consecutive GITMO trial. Leukemia 20:1840-1847, 2006
16. Bhatia S, Robison LL, Francisco L, et al: Late mortality in survivors of autologous hematopoieticcell transplantation: Report from the Bone Marrow Transplant Survivor Study. Blood 105:4215-4222, 2005
17. Lu X, Ma O, Nguyen T-A, et al: The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 12:342-354, 2007
18. Oliva-Trastoy M, Berthonaud V, Chevalier A, et al: The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase. Oncogene 26:1449-1458, 2007
19. Ruark E, Snape K, Humburg P, et al: Mosaic PPM1D mutations are associatedwith predisposition to breast and ovarian cancer. Nature 493:406-410, 2013
20. Lillington DM, Micallef IN, Carpenter E, et al: Detection of chromosome abnormalities pre-highdose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma. J Clin Oncol 19:2472-2481, 2001
21. Mach-Pascual S, Legare RD, Lu D, et al: Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: A single institution study. Blood 91:4496-4503, 1998
22. Swisher EM, Harrell MI, Norquist BM, et al: Somatic mosaic mutations in PPM1D and TP53 in the blood of women with ovarian carcinoma. JAMA Oncol 2:370-372, 2016
23. Pharoah P D P, Song H, Dicks E, et al: PPM1D mosaic truncating variants in ovarian cancer cases may be treatment-related somatic mutations. J Natl Cancer Inst 108: djv347, 2016
24. Zajkowicz A, Butkiewicz D, Drosik A, et al: Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients. Br J Cancer 112:1114-1120, 2015